1. Home
  2. SVRE vs DRMA Comparison

SVRE vs DRMA Comparison

Compare SVRE & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SaverOne 2014 Ltd.

SVRE

SaverOne 2014 Ltd.

HOLD

Current Price

$0.92

Market Cap

1.8M

Sector

N/A

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$2.51

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SVRE
DRMA
Founded
2014
2014
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8M
2.1M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
SVRE
DRMA
Price
$0.92
$2.51
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
64.9K
54.5K
Earning Date
12-21-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$580,536.00
N/A
Revenue This Year
$453.30
N/A
Revenue Next Year
$106.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
13.19
N/A
52 Week Low
$0.77
$2.34
52 Week High
$63.60
$23.70

Technical Indicators

Market Signals
Indicator
SVRE
DRMA
Relative Strength Index (RSI) 38.69 33.27
Support Level $0.86 $2.92
Resistance Level $0.98 $3.16
Average True Range (ATR) 0.09 0.29
MACD 0.01 0.05
Stochastic Oscillator 53.94 22.56

Price Performance

Historical Comparison
SVRE
DRMA

About SVRE SaverOne 2014 Ltd.

Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road and pedestrians. Geographially, it operates in Israel and Europe, out of which it derives maximum revenue from Israel.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

Share on Social Networks: